1 study found for:    20859679 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Recruiting DETECT III - A Multicenter, Phase III Study to Compare Standard Therapy +/- Lapatinib in HER2-ve MBC-Patients With HER2+ve CTCs
Conditions: HER2-negative Metastatic Breast Cancer;   HER2-positive Circulating Tumor Cells
Interventions: Drug: standard chemo- or endocrine therapy;   Drug: standard chemo- or endocrine therapy + Lapatinib

Indicates status has not been verified in more than two years